Skip to main content
SkinBioTherapeutics plc (AIM:SBTX)
London flag London · Delayed Price · Currency is GBP · Price in GBX
12.85
+2.10 (19.52%)
Mar 6, 2026, 12:52 PM GMT

SkinBioTherapeutics Income Statement

Millions GBP. Fiscal year is Jul - Jun.
Fiscal Year
 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2020 - 2016
Period Ending
 Jun '25 Jun '24 Jun '23 Jun '22 Jun '21 2020 - 2016
Operating Revenue
4.641.210.130.07-
Upgrade
Revenue
4.641.210.130.07-
Upgrade
Revenue Growth (YoY)
283.74%815.26%76.64%--
Upgrade
Cost of Revenue
1.780.530.050.03-
Upgrade
Gross Profit
2.860.680.090.05-
Upgrade
Selling, General & Admin
3.863.032.152.170.99
Upgrade
Research & Development
0.130.560.930.860.51
Upgrade
Operating Expenses
3.983.593.083.031.5
Upgrade
Operating Income
-1.12-2.91-3-2.98-1.5
Upgrade
Interest Expense
-0.09-0.04-0.01-0.01-0
Upgrade
EBT Excluding Unusual Items
-1.22-2.95-3.01-2.99-1.5
Upgrade
Other Unusual Items
0.5----
Upgrade
Pretax Income
-0.72-2.95-3.01-2.99-1.5
Upgrade
Income Tax Expense
-0.02-0.07-0.17-0.2-0.07
Upgrade
Net Income
-0.7-2.88-2.84-2.79-1.43
Upgrade
Net Income to Common
-0.7-2.88-2.84-2.79-1.43
Upgrade
Shares Outstanding (Basic)
228186165157147
Upgrade
Shares Outstanding (Diluted)
228186165157147
Upgrade
Shares Change (YoY)
22.32%13.10%5.06%6.87%14.53%
Upgrade
EPS (Basic)
-0.00-0.02-0.02-0.02-0.01
Upgrade
EPS (Diluted)
-0.00-0.02-0.02-0.02-0.01
Upgrade
Free Cash Flow
-1.24-2.74-2.73-2.67-1.56
Upgrade
Free Cash Flow Per Share
-0.01-0.01-0.02-0.02-0.01
Upgrade
Gross Margin
61.65%56.51%64.51%60.64%-
Upgrade
Operating Margin
-24.21%-240.36%-2271.26%-3988.83%-
Upgrade
Profit Margin
-15.01%-237.95%-2146.91%-3735.37%-
Upgrade
Free Cash Flow Margin
-26.76%-226.80%-2071.02%-3575.44%-
Upgrade
EBITDA
-0.82-2.77-2.99-2.98-1.5
Upgrade
EBITDA Margin
-17.65%-229.38%---
Upgrade
D&A For EBITDA
0.30.130.0100
Upgrade
EBIT
-1.12-2.91-3-2.98-1.5
Upgrade
EBIT Margin
-24.21%-240.36%---
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.